BioLineRx (BLRX) Enterprise Value: 2023-2025
Historic Enterprise Value for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$11.2 million.
- BioLineRx's Enterprise Value fell 233.29% to -$11.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$86.3 million, marking a year-over-year increase of 15.59%. This contributed to the annual value of -$2.4 million for FY2024, which is 104.52% down from last year.
- As of Q2 2025, BioLineRx's Enterprise Value stood at -$11.2 million, which was up 27.36% from -$15.4 million recorded in Q1 2025.
- Over the past 5 years, BioLineRx's Enterprise Value peaked at $65.4 million during Q3 2023, and registered a low of -$15.4 million during Q1 2025.
- Moreover, its 3-year median value for Enterprise Value was $22.7 million (2023), whereas its average is $26.8 million.
- As far as peak fluctuations go, BioLineRx's Enterprise Value surged by 89.84% in 2024, and later tumbled by 233.29% in 2025.
- Quarterly analysis of 3 years shows BioLineRx's Enterprise Value stood at $54.2 million in 2023, then slumped by 104.52% to -$2.4 million in 2024, then tumbled by 233.29% to -$11.2 million in 2025.
- Its Enterprise Value was -$11.2 million in Q2 2025, compared to -$15.4 million in Q1 2025 and -$2.4 million in Q4 2024.